Alpitatug
Based on 1 Customer Validation
Alpitatug (IMC 3C5) is a fully human monoclonal antibody and also a VEGFR3 inhibitor. Alpitatug blocks renal lymphangiogenesis, prevents the formation of tubulointerstitial lymphatic vessels, and reduces the number of lymphatic vessels in rats. Alpitatug does not alter the proteinuria level, inflammatory cell infiltration, fibrosis markers or renal function parameters in proteinuric rats. Alpitatug can be used in research related to proteinuric nephropathy and advanced solid tumors.
For research use only. We do not sell to patients.
- Purity : 99.13%
- CAS No.: 2921676-05-1
- Molecular Weight:145.30 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
KLK2/Kallikrein 2
In Vivo
Alpitatug (40 mg/kg; i.p.; three times per week; 6 weeks) significantly reduces lymphatic vessel number in healthy male Wistar rats without impacting renal inflammatory or fibrotic markers[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (3-month-old male, 180-200 g, chronic kidney disease induced by single tail vein injection of 1.8 mg/kg adriamycin)[1]
-
Dosage:40 mg/kg
-
Administration:i.p.; three times per week; 6 weeks
-
Result:Completely prevented tubulointerstitial lymphatic vessel formation in proteinuric rats, with a significant reduction in mean LV number compared to untreated proteinuric rats (P<0.001).
Reduced LV number in healthy treated rats compared to untreated healthy controls (P<0.001).
Showed no significant changes in proteinuria, body weight, blood pressure, heart rate, food/fluid intake, or creatinine clearance compared to untreated proteinuric rats.
Exhibited a non-significant trend toward reduced ED1-positive macrophages, no marked change in CD3-positive T-cell number, and no significant effects on α-SMA-positive myofibroblast accumulation, collagen III deposition, or interstitial fibrosis (PAS staining score).
Showed a near-significant reduction in collagen III (α1) mRNA expression, but no significant effects on collagen I (α1), TGF-β1, VCAM-1, MCP-1/CCL2, or osteopontin mRNA expression.
Showed no significant differences in total white blood count, lymphocytes, neutrophils, basophils, or eosinophils.
-
Animal Model:Wistar rats (3-month-old male, 180-200 g, healthy)[1]
-
Dosage:40 mg/kg
-
Administration:i.p.; three times per week; 6 weeks
-
Result:Significantly reduced mean LV number in healthy rats compared to untreated healthy controls (P<0.001).
Showed no significant changes in body weight, blood pressure, heart rate, food/fluid intake, or creatinine clearance compared to untreated healthy rats.
Exhibited a non-significant trend toward reduced ED1-positive macrophages, no marked change in CD3-positive T-cell number, and no significant effects on α-SMA-positive myofibroblast accumulation, collagen III deposition, or interstitial fibrosis (PAS staining score).
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human Kallikrein can bind Alpitatug. The EC50 for this effect is 227.9 ng/mL. -
Flow cytometric analysis of 1.5×106 HT-29 cells with Alpitatug (HY-P990608, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2921676-05-1
-
Appearance Liquid
-
Molecular Weight 145.30 kDa
-
Color Colorless to light yellow
-
Synonyms
IMC 3C5; JNJ-69086420 antibody; Anti-KLK2 Antibody (h11B6)
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)